Get the Daily Brief
Latest Biotech News
TIL therapy advances — FDA nod meets manufacturing and access bottlenecks
The tumor‑infiltrating lymphocyte (TIL) field has gained momentum with recent regulatory approvals, but experts say operational, manufacturing and access challenges persist. The review highlights...
IDR‑mediated condensation boosts CAR‑T potency against low‑antigen tumors
A Nature Chemical Biology study showed intracellular delivery of multivalent Intrinsically Disordered Regions (IDRs) induces condensate formation that enhances CAR‑T cytotoxicity against...
Intranasal nanogel therapeutic vaccine prevents HPV‑driven cervical tumors in preclinical models
Chiba University researchers reported a cationic nanogel (cCHP) intranasal vaccine delivering HPV16 E7 antigen with cyclic‑di‑AMP adjuvant that prevented cervical tumor development in mice and...
Merck buys Cidara: $9.2B deal adds long‑acting influenza antiviral
Merck agreed to acquire Cidara Therapeutics for about $9.2 billion to add CD388, a long‑acting neuraminidase inhibitor–Fc conjugate, to its antiviral portfolio. CD388 is in Phase III (ANCHOR) as a...
Korro collapses: Data miss triggers 81% slide, cuts and pivot
Korro Bio’s shares plunged 81% after Phase I/IIa REWRITE data for KRRO‑110 fell short of projections in alpha‑1 antitrypsin deficiency (AATD). The company disclosed protein increases below the...
Sofinnova raises €650M: New flagship fund backs preclinical life sciences
Paris‑based Sofinnova Partners closed €650 million ($750 million) for its Capital XI fund to back preclinical biotech and a slice of medtech. The firm has already deployed capital into five...
Iambic raises $100M: AI‑discovered oncology candidate moves toward trials
Iambic secured $100 million to advance clinical trials of cancer drugs discovered using its AI platform, following presentation of breast cancer data at the European Society for Medical Oncology...
Point‑of‑care AAV8 antibody test: Tackles a key gene‑therapy bottleneck
Researchers developed a point‑of‑care (POC) test using Chembio’s Dual Path Platform to detect AAV8 binding antibodies in plasma, serum and whole blood. The assay enables rapid screening for...
AAV variants boost vascular delivery: Two studies report improved transduction
Teams publishing in Gene Therapy reported engineered AAV variants that substantially improve transduction of human vascular endothelial cells. Stamataki et al. screened and identified capsid...
Microglial CARs... Enhance amyloid clearance in preclinical models
Researchers engineered microglia with chimeric antigen receptors (CARs) to selectively phagocytose Aβ1‑42, reporting increased uptake of pathogenic amyloid species in vitro and in vivo models. The...
Condensing CAR‑T potency: IDR strategy boosts activity against low‑antigen tumors
A Nature Chemical Biology study showed that intracellular delivery of multivalent binding agents using intrinsically disordered regions (IDRs) promotes condensate formation that enhances CAR‑T...
AAV microdystrophin therapy update: Elevidys signals gene‑therapy momentum
Regulatory and clinical history around AAV microdystrophin therapies continues to shape the Duchenne muscular dystrophy (DMD) landscape after the FDA granted accelerated approval to...
Prime‑editing inversion method: PIE enables chromosome‑scale DNA flips
Researchers introduced Prime‑Editing‑Based Inversion with Enhanced Performance (PIE), a technique that enables efficient, large‑scale inversion of genomic DNA in mammalian cells. PIE improves on...
Merck to acquire Cidara for $9.2B — Adds long‑acting flu antiviral
Merck agreed to buy Cidara Therapeutics for approximately $9.2 billion to add the long‑acting influenza prophylactic CD388 to its antiviral portfolio. Cidara’s CD388—a small‑molecule neuraminidase...
Sofinnova closes €650M fund — Capital XI backs preclinical drugmakers and medtech
Sofinnova Partners raised €650 million (about $750 million) for its Capital XI fund to invest in preclinical life‑science startups, allocating roughly 20%–30% toward medical devices. The firm has...
Korro stock collapses 81% after underwhelming RNA‑editing data
Korro Bio’s shares plunged 81% after topline data from its Phase I/IIa REWRITE trial showed KRRO‑110 produced functional M‑AAT protein but failed to reach the protective 11 µM AAT threshold. The...
Iambic raises $100M to move AI‑designed oncology candidates into trials
AI drug‑discovery startup Iambic closed a $100 million financing to fund clinical development of oncology candidates discovered by its generative chemistry platform. The round follows...
AAV vector toolkit expands — Point‑of‑care antibody test and new capsids for vascular transduction
Researchers introduced two advances that address key bottlenecks in AAV gene therapy: a rapid point‑of‑care test for AAV8 binding antibodies and discovery of AAV capsid variants that improve...
Gene‑editing toolkit widens — Collagen disorder therapies and chromosomal‑scale inversions
Two independent papers advance genome‑editing approaches: a review outlining progress and prospects for gene editing in collagen disorders and a methods paper describing Prime‑Editing‑Based...
CAR platform advances: intracellular condensation and microglial CARs
New preclinical studies report two distinct routes to improve chimeric antigen receptor (CAR) strategies. A Nature Chemical Biology paper shows that intracellular delivery of multivalent...